The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma

Molecular Cancer Therapeutics

Volumn 7, Issue 8, 2008, Pages 2405-2414

  Mei, Szu Chieh ^a   Wu, Rong Tsun ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIPOSOME; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENCAPSULATION; FEMALE; GENETIC TRANSCRIPTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA TRANSLATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; FIBROBLAST GROWTH FACTOR 2; GLIOMA; GUANINE; HUMANS; PROMOTER REGIONS, GENETIC; THALIDOMIDE; TRANSCRIPTION, GENETIC;

EID: 53349089866     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2398     Document Type: Article

References (47)

1. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
3. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002;53:629-57.
4. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15.
5. Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001;7:2675-81.
6. Sato N, Hattori Y, Wenlin D, et al. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity. Jpn J Cancer Res 2002;93:459-66.
7. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol 1992;151:81-93.
8. Quarto N, Fong KD, Longaker MT. Gene profiling of cells expressing different FGF-2 forms. Gene 2005;356:49-68.
9. Mukdsi JH, De Paul AL, Petiti JP, et al. Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas. Acta Neuropathol (Berl) 2006;112:491-501.
10. Yamanaka Y, Friess H, Buchler M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5289-96.
11. Hokari M, Matsuda Y, Wakai T, et al. Tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 potentates the anchorage-independent growth of human hepatoma HepG2 cells. Life Sci 2007;81:336-45.
12. Florkiewicz RZ, Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A 1989;86:3978-81.
13. Vagner S, Gensac MC, Maret A, et al. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol 1995;15:35-44.
14. Bakay B, Nyhan WL. Binding of thalidomide by macromolecules in the fetal and maternal rat. J Pharmacol Exp Ther 1968;161:348-60.
15. Huang PH, McBride WG, Tuman WG. Interaction of thalidomide with DNA of rabbit embryos: a possible explanation for its immunosuppressant and teratogenic effects. Pharmacol Toxicol 1999;85:103-4.
16. Drucker L, Uziel O, Tohami T, et al. Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. Mol Pharmacol 2003;64:415-20.
17. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000;59:1489-99.
18. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
19. Fang JY, Hung CF, Hwang TL, Huang YL. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 2005;13:19-27.
20. Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 1998;213:157-67.
21. Ke LD, Shi YX, Im SA, et al. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 2000;6:2562-72.
22. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005;23:5334-46.
23. Eriksson T, Bjorkman S, Roth B, et al. Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998;10:223-8.
24. Renko M, Quarto N, Morimoto T, Rifkin DB. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol 1990;144:108-14.
25. Murphy PR, Sato Y, Knee RS. Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line. Mol Endocrinol 1992;6:877-84.
26. Vagner S, Touriol C, Galy B, et al. Translation of CUG- but not AUG-initiated forms of human fibroblast growth factor 2 is activated in transformed and stressed cells. J Cell Biol 1996;135:1391-402.
27. Kelm JM, Timmins NE, Brown CJ, et al. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 2003;83:173-80.
28. Creancier L, Morello D, Mercier P, Prats AC. Fibroblast growth factor 2 internal ribosome entry site (IRES) activity ex vivo and in transgenic mice reveals a stringent tissue-specific regulation. J Cell Biol 2000;150:275-81.
29. Usha S, Johnson IM, Malathi R. Interaction of resveratrol and genistein with nucleic acids. J Biochem Mol Biol 2005;38:198-205.
30. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol 2004;15:1151-60.
31. Kakimoto T, Hattori Y, Okamoto S, et al. Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res 2002;93:1029-36.
32. Huang PH, McBride WG. Thalidomide induced alteration in secondary structure of rat embryonic DNA in vivo. Teratog Carcinog Mutagen 1990;10:281-94.
33. Bonnal S, Schaeffer C, Creancier L, et al. A single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons. J Biol Chem 2003;278:39330-6.
34. Komar AA, Hatzoglou M. Internal ribosome entry sites in cellular mRNAs: mystery of their existence. J Biol Chem 2005;280:23425-8.
35. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974;3:355-9.
36. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 2002;7:247-60.
37. Wang LH. Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 2004;71:361-7.
38. Bikfalvi A, Klein S, Pintucci G, et al. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms. J Cell Biol 1995;129:233-43.
39. Quarto N, Talarico D, Florkiewicz R, Rifkin DB. Selective expression of high molecular weight basic fibroblast growth factor confers a unique phenotype to NIH 3T3 cells. Cell Regul 1991;2:699-708.
40. Nesbit M, Nesbit HK, Bennett J, et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999;18:6469-76.
41. Ropiquet F, Berthon P, Villette JM, et al. Constitutive expression of FGF2/bFGF in non-tumorigenic human prostatic epithelial cells results in the acquisition of a partial neoplastic phenotype. Int J Cancer 1997;72:543-7.
42. Arese M, Chen Y, Florkiewicz RZ, et al. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell 1999;10:1429-44.
43. Fukui S, Nawashiro H, Otani N, et al. Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. Cancer 2003;97:3061-7.
44. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
45. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998;141:1659-73.
46. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78.
47. Tsunoda S, Nakamura T, Sakurai H, Saiki I. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci 2007;98:541-8.